312529-09-2

Basic information

• Product Name: tert-butyl (benzyloxy) (phenethyl)carbamate
• Synonyms: tert-butyl (benzyloxy) (phenethyl)carbamate
• CAS NO: 312529-09-2
• Molecular Weight: 327.423
• Mol File: 312529-09-2.mol

Chemical Properties

• CAS DataBase Reference: tert-butyl (benzyloxy) (phenethyl)carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl (benzyloxy) (phenethyl)carbamate(312529-09-2)
• EPA Substance Registry System: tert-butyl (benzyloxy) (phenethyl)carbamate(312529-09-2)

Safety Data

• Hazardous Substances Data: 312529-09-2(Hazardous Substances Data)

Upstream product

• 79722-21-7 tert-butyl N-(benzyloxy)carbamate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 2687-43-6 O-benzylhydoxylamine hydrochloride 
• 103-63-9 1-phenyl-2-bromoethane 
• 51-67-2 tyrosamine 
• 100-39-0 benzyl bromide 

Downstream Products

• 82543-02-0 N-hydroxy-N-phenethylacetamide 
• 312529-04-7 N-(benzotriazol-1-yl-cyclopropyl-methyl)-O-benzyl-N-phenethyl-hydroxylamine 
• 312528-98-6 N-benzotriazol-1-ylmethyl-O-benzyl-N-phenethyl-hydroxylamine 
• 312529-03-6 N-(1-benzotriazol-1-yl-ethyl)-O-benzyl-N-phenethyl-hydroxylamine 
• 312529-01-4 N,O-dibenzyl-N-phenethylhydroxylamine 
• 92646-29-2 O-benzyl-N-(2-phenylethyl)hydroxylamine 

Relevant articles and documents

Structure Property Relationships of Carboxylic Acid Isosteres

The replacement of a carboxylic acid with a surrogate structure, or (bio)-isostere, is a classical strategy in medicinal chemistry. The general underlying principle is that by maintaining the features of the carboxylic acid critical for biological activity, but appropriately modifying the physicochemical properties, improved analogs may result. In this context, a systematic assessment of the physicochemical properties of carboxylic acid isosteres would be desirable to enable more informed decisions of potential replacements to be used for analog design. Herein we report the structure-property relationships (SPR) of 35 phenylpropionic acid derivatives, in which the carboxylic acid moiety is replaced with a series of known isosteres. The data set generated provides an assessment of the relative impact on the physicochemical properties that these replacements may have compared to the carboxylic acid analog. As such, this study presents a framework for how to rationally apply isosteric replacements of the carboxylic acid functional group.

Structural Requirements of Histone Deacetylase Inhibitors: SAHA Analogs Modified on the Hydroxamic Acid

Histone deacetylase (HDAC) proteins have emerged as targets for anti-cancer therapeutics, with several inhibitors used in the clinic, including suberoylanilide hydroxamic acid (SAHA, vorinostat). Because SAHA and many other inhibitors target all or most o

SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF

The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no- reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods.

Acyclic oxyiminium ions. Mannich reactions and addition of grignard reagents

Acyclic oxyiminium ion generation from secondary hydroxylamines (4a,b and 6a,b) and formaldehyde in the presence of acetic acid is reported. Trapping these electrophiles with 2-methyl furan, pyrrole or indole affords a series of novel O-benzyl tertiary hydroxylamines in good to excellent yield. Benzotriazole mediated synthetic methodology has also been successfully developed to generate oxyiminium ions which react with Grignard reagents, to give novel O-benzyl tertiary hydroxylamines. (C) 2000 Elsevier Science Ltd.